Daily Cosmetic Research Analysis
Safety in aesthetic medicine dominated today’s most impactful papers: a systematic review characterizes alopecia after cosmetic injections, and a cadaveric micro-CT study proposes an anatomically guided protocol for retrobulbar hyaluronidase in filler-induced visual loss. A network pharmacology–guided, multi-herb extract showed multi-target anti-acne activities, suggesting an evidence-based path for future cosmeceutical development.
Summary
Safety in aesthetic medicine dominated today’s most impactful papers: a systematic review characterizes alopecia after cosmetic injections, and a cadaveric micro-CT study proposes an anatomically guided protocol for retrobulbar hyaluronidase in filler-induced visual loss. A network pharmacology–guided, multi-herb extract showed multi-target anti-acne activities, suggesting an evidence-based path for future cosmeceutical development.
Research Themes
- Injection safety and adverse events in aesthetic practice
- Anatomy-guided emergency interventions for filler complications
- Network pharmacology–guided cosmeceutical discovery for acne
Selected Articles
1. Alopecia Induced by Cosmetic Injection Procedures: A Comprehensive Review.
This review aggregates 25 reports (48 patients) of alopecia following cosmetic injection procedures, organizing data on materials, sites, timing, mechanisms, management, and outcomes. It emphasizes underreporting and the need for clinician awareness, prevention, and ready-to-implement treatment algorithms.
Impact: It consolidates scattered evidence of a rising but underrecognized complication, directly informing consent, risk mitigation, and early management in aesthetic practice.
Clinical Implications: Supports informed consent regarding rare alopecia risk, encourages injection techniques minimizing ischemia, and guides early recognition and treatment pathways for better hair salvage.
Key Findings
- Identified 25 publications describing 48 patients with alopecia after cosmetic injections.
- Synthesized data across filler types, injection/anatomic sites, onset, symptoms, proposed mechanisms, management, and outcomes.
- Highlights underreporting and calls for prevention and standardized management strategies.
Methodological Strengths
- Multi-database search (PubMed, Web of Science, Embase) with predefined selection criteria.
- Comprehensive extraction of clinical variables relevant to mechanism and management.
Limitations
- Evidence largely based on case reports/series with heterogeneous reporting.
- No meta-analysis or pooled effect estimates; risk factors and causality remain uncertain.
Future Directions: Establish prospective registries with standardized outcome reporting; develop consensus prevention and treatment algorithms and evaluate them in multicenter studies.
BACKGROUND: Alopecia resulting from cosmetic injections is a rare occurrence, yet its increasing prevalence highlights the need for understanding and managing this condition. This review seeks to clarify the known causes of alopecia following cosmetic procedures and the mechanisms involved. It also highlights the risk and draws attention to the growing number of reports linking cosmetic injections to post-procedure alopecia. METHODS: A search was conducted on PubMed, Web of Science, and Embase, and relevant articles published from January 2000 to November 2024 were selected based on predefined criteria. RESULTS: Twenty-five articles were identified, involving 48 patients who experienced alopecia due to cosmetic injection procedures. Data collected included filler type, injection site, site of complication, onset of alopecia, associated symptoms, auxiliary examinations, proposed mechanisms of alopecia, treatment modalities, and outcomes. CONCLUSION: Alopecia following cosmetic injection procedures is an underreported adverse effect. Physicians should be vigilant about this potential complication, recognize its manifestations, and have appropriate prevention and treatment strategies readily available. LEVEL OF EVIDENCE IV: The journal asks authors to assign a level of evidence to each article. For a complete description of Evidence-Based Medicine ratings, see the Table of Contents or the online Instructions for Authors at www.springer.com/00266 .
2. Anatomical Guideline for Retrobulbar Hyaluronidase Injection.
Cadaveric dissection plus micro-CT mapping defined a safe, standardized trajectory for retrobulbar hyaluronidase in filler-related central retinal artery occlusion: from inferolateral orbital rim toward superomedial quadrant using a 35 mm, 22–23G needle. The approach aims to avoid critical neurovascular structures and reduce globe injury risk.
Impact: Provides actionable, anatomy-based guidance for an emergency procedure to potentially reverse filler-induced visual loss, addressing a critical gap in standardized practice.
Clinical Implications: Supports training and protocolization of retrobulbar hyaluronidase use (trajectory, needle gauge/length) in multidisciplinary settings for filler emergencies.
Key Findings
- Inferolateral orbital approach minimizes risk to extraocular muscles and neurovascular structures.
- Optimal trajectory: from inferolateral orbital rim toward the superomedial quadrant.
- Recommended instrument: 35 mm length, 22–23G needle to reach retrobulbar space with reduced perforation risk.
Methodological Strengths
- Integration of cadaveric dissection with high-resolution micro-CT mapping.
- Focus on clinically relevant anatomic relationships for procedural safety.
Limitations
- Cadaveric study without clinical outcome validation.
- Anatomical variability and operator skill were not assessed in live scenarios.
Future Directions: Prospective evaluation of visual and perfusion outcomes after protocolized retrobulbar hyaluronidase; development of training simulations and decision algorithms.
BACKGROUND: Vision loss following cosmetic filler injections is a rare but devastating complication resulting from inadvertent intravascular embolization, most often affecting the ophthalmic artery. Retrobulbar hyaluronidase injection has been proposed as an emergency intervention, yet anatomical guidelines for its administration remain poorly defined. OBJECTIVE: To propose an anatomically informed protocol for safe and effective retrobulbar hyaluronidase injection in cases of filler-induced central retinal artery occlusion. METHODS: Cadaveric dissections and micro-CT imaging were used to map orbital anatomy, focusing on the spatial relationship between the optic nerve, ophthalmic artery, and adjacent structures. The inferolateral quadrant was identified as the safest trajectory for retrobulbar injection, minimizing risk to ocular muscles and nerves. RESULTS: The optimal needle trajectory was from the inferolateral orbital rim toward the superior medial quadrant, avoiding critical neurovascular structures. A 35 mm, 22-23G needle was deemed appropriate for reaching the retrobulbar space while minimizing the risk of globe perforation. CONCLUSION: This study provides a standardized anatomical approach for retrobulbar hyaluronidase injection, aiming to improve safety and potentially restore perfusion in acute filler-induced visual loss. Clinical implementation should proceed with caution and in multidisciplinary settings.
3. Potential Cosmetic Applications of the Combined Extract of Panax ginseng, Ganoderma lucidum, Cordyceps militaris, and Several Asian Plants.
Using HPLC, network pharmacology, docking, and in vitro assays, a combined herbal extract (PGC) showed multi-target anti-acne effects: antibacterial activity against Cutibacterium acnes (MIC 25 μg/mL), barrier restoration (filaggrin +235%, loricrin +261%), reduced ROS and lipid accumulation, enhanced keratinocyte migration, and no cytotoxicity ≤200 μg/mL.
Impact: Demonstrates an evidence-based, network pharmacology–guided approach to formulate multitarget cosmeceuticals for acne, linking mechanistic predictions with functional assays.
Clinical Implications: Suggests a candidate multitarget topical ingredient for acne-prone skin; however, in vivo efficacy and safety data are needed before clinical or consumer use.
Key Findings
- Batch-consistent PGC contained phenolic acids, flavonoids, and alkaloids by HPLC.
- Network pharmacology/docking indicated IL-17/TNF/NF-κB axis modulation as a multitarget mechanism.
- Antibacterial activity against Cutibacterium acnes (MIC = 25 μg/mL) and barrier restoration (filaggrin +235%, loricrin +261%; 85% recovery from SDS damage).
- Reduced ROS (−45%), lipid droplets (−60%), and NO (−40%) with enhanced keratinocyte migration (+40%); no cytotoxicity ≤200 μg/mL.
Methodological Strengths
- Integration of HPLC characterization, in silico network pharmacology/docking, and multiple functional in vitro assays.
- Quantitative readouts across antimicrobial, barrier, oxidative stress, lipid, and inflammatory endpoints.
Limitations
- Preclinical in vitro study without animal or human validation.
- Complex multi-herb composition may face batch standardization and regulatory hurdles.
Future Directions: Conduct in vivo efficacy/toxicity studies, develop stable topical formulations, and progress to randomized clinical trials in acne.
OBJECTIVE: Although bioactive compounds from single herbs are extensively explored in cosmetics, the synergistic potential of herbal combinations remains understudied. This study aimed to evaluate the stability of a combined extract of Panax ginseng, Ganoderma lucidum, Cordyceps militaris, and several Asian plants (PGC), and its multifunctional efficacy for acne-related skin dysfunction. METHODS: PGC was analyzed using high-performance liquid chromatography (HPLC) for batch consistency and bioactive quantification. Network pharmacology and molecular docking were used to identify active components and targets and assess binding affinities, respectively. In vitro assays were conducted to evaluate antibacterial activity, skin barrier repair, keratinocyte migration, reactive oxygen species (ROS) reduction, anti-inflammatory effects, and inhibition of lipid accumulation. The safety was tested via cytotoxicity assessments. RESULTS: HPLC analysis validated batch consistency and identified key bioactive constituents in PGC, including phenolic acids, flavonoids, and alkaloids. Integrated network pharmacology and molecular docking revealed multitarget mechanisms through the regulation of the IL-17/TNF/NF-κB axis pathway modulation. PGC exhibited potent antibacterial efficacy against acne-associated pathogens (Cutibacterium acne, MIC = 25 μg/mL), restored skin barrier integrity (filaggrin, +235%; loricrin, +261%), and sodium dodecyl sulfate (SDS)-induced damage (85%). Concurrently, PGC accelerated keratinocyte migration (40%), reduced ROS (45%) and abnormal lipid droplet content (60%), and attenuated inflammatory responses (40% nitric oxide (NO) inhibition) while maintaining biosafety (no cytotoxicity ≤ 200 μg/mL). CONCLUSION: PGC exemplified the translational potential of herbal compatibility, offering a multitargets solution for acne management through integrating antibacterial, barrier-repair, anti-inflammatory actions, and several other effects. This study established a network pharmacology-guided framework for developing evidence-based multitargets cosmetics.